PARP Inhibitors in Ovarian Cancer: A Review

por O’Malley, David M., Krivak, Thomas C., Kabil, Nashwa, Munley, Jiefen, Moore, Kathleen N.
Publicado 2023

Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers

por Kunos, Charles A., Andrews, Stephen J., Moore, Kathleen N., Chon, Hye Sook, Ivy, S. Percy
Publicado 2019

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

por Banerjee, Susana, Gonzalez-Martin, Antonio, Harter, Philipp, Lorusso, Domenica, Moore, Kathleen N, Oaknin, Ana, Ray-Coquard, Isabelle
Publicado 2020

Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary...

por Coward, Jermaine I., Barve, Minal A., Kichenadasse, Ganessan, Moore, Kathleen N., Harnett, Paul R., Berg, Daniel, Garner, James S., Dizon, Don S.
Publicado 2021

Neoadjuvant immunotherapy of locoregionally advanced solid tumors

por Tarhini, Ahmad A, Eads, Jennifer R, Moore, Kathleen N, Tatard-Leitman, Valerie, Wright, John, Forde, Patrick M, Ferris, Robert L
Publicado 2022

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours

por Moore, Kathleen N, Bauer, Todd M, Falchook, Gerald S, Chowdhury, Swapan, Patel, Chirag, Neuwirth, Rachel, Enke, Aaron, Zohren, Fabian, Patel, Manish R
Publicado 2018

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

por Bendell, Johanna C., Patel, Manish R., Moore, Kathleen N., Chua, Cynthia C., Arkenau, Hendrik‐Tobias, Dukart, Gary, Harrow, Kim, Liang, Chris
Publicado 2018

Safety and management of niraparib monotherapy in ovarian cancer clinical trials

por Monk, Bradley J, González-Martin, Antonio, Buckley, Lynn, Matulonis, Ursula A., Rimel, B J, Wu, Xiaohua, Moore, Kathleen N, Mirza, Mansoor R
Publicado 2023

Overcoming the challenges of drug development in platinum-resistant ovarian cancer

por Eskander, Ramez N., Moore, Kathleen N., Monk, Bradley J., Herzog, Thomas J., Annunziata, Christina M., O’Malley, David M., Coleman, Robert L.
Publicado 2023

Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and...

por Cohen, Ezra EW, Moore, Kathleen N, Slomovitz, Brian M, Chung, Christine H, Anderson, Matthew L, Morris, Shannon R, Mauro, David, Burtness, Barbara
Publicado 2015

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

por Shah, Manisha H., Lorigan, Paul, O’Brien, Mary E. R., Fossella, Frank V., Moore, Kathleen N., Bhatia, Shailender, Kirby, Maurice, Woll, Penella J.
Publicado 2016

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer

por Gordhandas, Sushmita B., Manning-Geist, Beryl, Henson, Christina, Iyer, Gopa, Gardner, Ginger J., Sonoda, Yukio, Moore, Kathleen N., Aghajanian, Carol, Chui, M. Herman, Grisham, Rachel N.
Publicado 2022

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the F...

por Martin, Lainie P., Konner, Jason A., Moore, Kathleen N., Seward, Shelly M., Matulonis, Ursula A., Perez, Raymond P., Su, Ying, Berkenblit, Anna, Ruiz-Soto, Rodrigo, Birrer, Michael J.
Publicado 2017

COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies

por Monk, Bradley J., Coleman, Robert L., Moore, Kathleen N., Herzog, Thomas J., Secord, Angeles Alvarez, Matulonis, Ursula A., Slomovitz, Brian M., Guntupalli, Saketh R., O'Malley, David M.
Publicado 2020

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

por Bendell, Johanna C, Patel, Manish R, Infante, Jeffrey R, Kurkjian, Carla D, Jones, Suzanne F, Pant, Shubham, Burris, Howard A, Moreno, Ofir, Esquibel, Vanessa, Levin, Wendy, Moore, Kathleen N
Publicado 2015

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

por Fu, Siqing, Corr, Bradley R., Culm-Merdek, Kerry, Mockbee, Colleen, Youssoufian, Hagop, Stagg, Robert, Naumann, R. Wendel, Wenham, Robert M., Rosengarten, Rafael D., Benjamin, Laura, Hamilton, Erika Paige, Moore, Kathleen N.
Publicado 2022

Sparse feature selection for classification and prediction of metastasis in endometrial cancer

por Ahsen, Mehmet Eren, Boren, Todd P., Singh, Nitin K., Misganaw, Burook, Mutch, David G., Moore, Kathleen N., Backes, Floor J., McCourt, Carolyn K., Lea, Jayanthi S., Miller, David S., White, Michael A., Vidyasagar, Mathukumalli
Publicado 2017

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study

por You, Benoit, Sehgal, Vasudha, Hosmane, Balakrishna, Huang, Xin, Ansell, Peter J., Dinh, Minh H., Bell-McGuinn, Katherine, Luo, Xizhi, Fleming, Gini F., Friedlander, Michael, Bookman, Michael A., Moore, Kathleen N., Steffensen, Karina D., Coleman, Robert L., Swisher, Elizabeth M.
Publicado 2023

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

por Bauer, Todd M., Moore, Kathleen N., Rader, Janet S., Simpkins, Fiona, Mita, Alain C., Beck, J. Thaddeus, Hart, Lowell, Chu, Quincy, Oza, Amit, Tinker, Anna V., Imedio, Esteban Rodrigo, Kumar, Sanjeev, Mugundu, Ganesh, Jenkins, Suzanne, Chmielecki, Juliann, Jones, Suzanne, Spigel, David, Fu, Siqing
Publicado 2023

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

por Hassan, Raffit, Blumenschein, George R., Moore, Kathleen N., Santin, Alessandro D., Kindler, Hedy L., Nemunaitis, John J., Seward, Shelly M., Thomas, Anish, Kim, Stella K., Rajagopalan, Prabhu, Walter, Annette O., Laurent, Dirk, Childs, Barrett H., Sarapa, Nenad, Elbi, Cem, Bendell, Johanna C.
Publicado 2020